GENE ONLINE|News &
Opinion
Blog

2022-07-14| Trials & Approvals

Amazon, Fred Hutchinson Begin Human Trial for Cancer Vaccine

by Joy Lin
Share To

Amazon and Seattle, Washington-based Fred Hutchinson Cancer Center has launched a clinical trial to assess its cancer vaccine in melanoma and breast cancer. Fred Hutchinson will sponsor the FDA-approved Phase 1 trial, in which Amazon is listed as a collaborator, according to a filing

The two are hoping to recruit 20 participants over the age of 18 with late-stage melanoma or hormone receptor positive, HER2- breast cancer that is either metastatic or does not respond to treatment. The trial is expected to be completed in November 2023. 

 

A Neoantigen Peptide Vaccine Against Cancer

 

Amazon and Fred Hutchinson’s investigational treatment is a personalized neoantigen peptide vaccine which uses multiple tumor-specific antigens. When given together with an adjuvant, the vaccine may induce multiple lines of T cells to mount an immune response against the patient’s tumor. 

In the trial, patients will receive the immunostimulant poly ICLC intramuscular once weekly in weeks when no vaccine is given. Patients are given the cancer vaccine once every 4 weeks, 2 weeks after starting poly ICLC. They will also receive Opdivo (nivolumab) every 2 or 4 weeks. The treatment regime will continue for 25 weeks, after which patients are followed up at 24, 36, and 48 weeks. 

Related article: Vaccines Against Cancers May Be the Future 

 

Amazon’s Push Into Healthcare 

 

Amazon has confirmed the partnership to CNBC, and said it will contribute scientific and machine learning expertise to the collaboration. Its cloud technology platform, Amazon Web Services (AWS), has been used by the Fred Hutch Microbiome Research Initiative — funded by Fred Hutchinson — to power a high-performance computing platform for microbiome analysis. Other users of the AWS include Moderna, Philips and the UK NHS.

Amazon has been expanding multilaterally in the healthcare industry, with the 2020 launch of an online pharmacy, as well as efforts to promote its telehealth service called Amazon Care. The company has developed a wearable health tracker called the Halo Band that helps users analyze their sleep, activity, nutrition, and more. Furthermore, the company is also looking to develop at-home diagnostic testing for diseases. 

Last year, the company captured attention when its ex-CEO Jeff Bezos was revealed as an investor in Altos Labs, a startup with the grand ambition to make people younger via anti-aging technology.

 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
AACR Showcases Breakthroughs in Novel Breast Cancer Diagnosis and Treatment Strategies
2024-04-09
Saudi Arabia Reveals Grand Ambition to Become a Global Biotech Powerhouse by 2040
2024-01-26
GeneOnline’s Pick – Top 10 Global Industry News Stories in 2023 (Part 2)
2024-01-15
LATEST
New Regulatory Measures in China A First in the Fight Against Sedentary Behavior in Children
2024-05-24
Cure Genetics Announced Promising Safety and Efficacy Data of CAR-NKT Product CGC729 for RCC at ASGCT 2024
2024-05-23
AstraZeneca’s $1.5 Billion ADC Manufacturing Facility in Singapore
2024-05-23
Hims & Hers Health Inc. Tipping the Scales of the Weight Loss Market — and Wall Street is Loving it!
2024-05-22
GV Announces Cooperation with CICC
2024-05-22
Eli Lilly and Aktis Oncology Partner to Advance Novel Radiopharmaceuticals
2024-05-22
Preventive Medicine for Neurodegeneration on the Rise: New Breakthrough in Routine Blood Testing for Alzheimer’s Disease
2024-05-20
EVENT
Scroll to Top